



**SOLUTION BRIEF**

# Micromedex IV Compatibility

Designed to support safe intravenous medication  
administration at the point of care

Micromedex® IV Compatibility is expertly designed to assist healthcare professionals in making quick, accurate decisions at the point of care. This ensures the safe administration of intravenous medications, backed by the trusted and reliable content of Micromedex.

**Key Features:**

- Enhanced Navigation and Clarity: New chart and list views offer easy navigation. Updated icons and improved clarity enhance user experience.
- Comprehensive Compatibility Information: Access compatibility information for Drug-Drug, Drug-Solution, and Parenteral Nutrition across various delivery methods, including Y-Site, Syringe, and Admixture.
- Informed Decision-Making: Make more informed, timely decisions with content powered by Trissel's™ 2 Clinical Pharmaceutics Database (Parenteral Compatibility) continuously updated by our robust editorial processes.



77,000+ compatibility results



Fully referenced content utilizing 5,000+ peer-reviewed articles and other sources



950+ parenteral drugs and solutions, including chemotherapy drugs



Micromedex IV Compatibility mobile app available for online customers



The National Institute for Health and Care Excellence (NICE) has accredited the process used by Micromedex by Merative.

Merative **Micromedex**®

Home Drug Interactions **IV Compatibility** Drug ID Drug Comparison CareNotes NeoFax® / Pediatrics Tox & Drug Product Lookup RED BO

< Modify Search

**IV Compatibility Results - Chart view**

Preparation and Storage Drugs:  
 ① DOPamine hydrochloride  
 ① Furosemide  
 ① Gentamicin Sulfate  
 ① PRECEDEX  
 ① ZOSYN

Filter results  
 Administrative Method  
 Y-Site  
 Admixture  
 Syringe  
 Compatibility  
 Compatible  
 Incompatible  
 Uncertain  
 Not Tested  
 Drugs  
 All (5) v  
 Apply Filters

Drug	dexmedetomidine hydrochloride	DOPamine hydrochloride	Furoser
dexmedetomidine hydrochloride	↓	Y-Site ✓ 1 Result	Y-Site ✓ 2 Re
DOPamine hydrochloride	→	Y-Site ✓ 1 Result	Y-Site ✓ 8 Re ✗ 6 Re
Furosemide	Y-Site ✓ 2 Results	Y-Site ✓ 8 Results ✗ 6 Results	
Gentamicin Sulfate	Y-Site ✓ 1 Result	Y-Site ✓ 4 Results	Y-Site ✓ 2 Re ✗ 7 Re
Piperacillin Sodium/Tazobactam Sodium	Y-Site ✓ 1 Result	Y-Site ✓ 1 Result	Y-Site ✓ 1 Re

Powered by Trissel's™ 2 Clinical Pharmaceutics Database (Parenteral Compatibility).

Merative **Micromedex**®

Home Drug Interactions **IV Compatibility** Drug ID Drug Comparison CareNotes NeoFax® / Pediatrics Tox & Drug Product Lookup

< Modify Search

**IV Compatibility Results - List view**

Preparation and Storage Drugs:  
 ① DOPamine hydrochloride  
 ① Furosemide  
 ① Gentamicin Sulfate  
 ① PRECEDEX  
 ① ZOSYN

Filter results  
 Administrative Method  
 Y-Site  
 Admixture  
 Syringe  
 Compatibility  
 Compatible  
 Incompatible  
 Uncertain

Drug	Y-Site
dexmedetomidine hydrochloride - DOPamine hydrochloride	✓ 1 Result
dexmedetomidine hydrochloride - Furosemide	✓ 2 Results
dexmedetomidine hydrochloride - Gentamicin Sulfate	✓ 1 Result
dexmedetomidine hydrochloride - Piperacillin Sodium/Tazobactam Sodium	✓ 1 Result
DOPamine hydrochloride - Furosemide	✓ 8 Results ✗ 6 Results

## View Detailed IV Monographs for storage and stability data

You can view detailed study information from multiple studies, including:

- Concentration
- Manufacturer
- Compatibility results
- Physical compatibility
- Chemical stability
- Method
- Storage
- Container
- Study period

Merative Micromedex®

Home	Drug Interactions	IV Compatibility	Drug ID	Drug Comparison	CareNotes	NeoFax® / Pediatrics	Tox & Drug Product Lookup	RED
------	-------------------	------------------	---------	-----------------	-----------	----------------------	---------------------------	-----

Reference: 80121

Notes: Variable compatibility results have been reported for this combination depending on the dopa

Study 8

Drug 1: **DOPamine hydrochloride**  
12.8mg/mL in Dextrose 5% in sodium chloride 0.45%  
Abbott Laboratories

Drug 2: **Furosemide**  
5mg/mL in Dextrose 5% in sodium chloride 0.45%  
American Regent

Status:

Information: **Physical Compatibility:**  
Physically compatible. No changes in measured haze or turbidity, particulates, or color were f

**Storage:**  
Ambient room temperature near 23 °C exposed to normal fluorescent light.

Test Parameters: **Container:**  
Simulated Y-site administration using glass test tubes.

**Study Period:**  
4 hours.

**Method:**  
Visual observation and electronic assessment.

Reference: 80121

Notes: Variable compatibility results have been reported for this combination depending on the dopa

Study 9

Drug 1: **DOPamine hydrochloride**  
12.8mg/mL in Dextrose 5% in Water  
American Regent

Drug 2: **Furosemide**  
5mg/mL in Dextrose 5% in Water  
Abbott Laboratories

Status:

Information: **Physical Compatibility:**  
Physically incompatible. White precipitation appeared immediately upon mixing.

**Storage:**  
Room temperature exposed to fluorescent light.

Test Parameters: **Container:**  
Simulated Y-site administration using glass test tubes.

**Study Period:**  
3 hours.

**Method:**  
Visual observation.

Reference: 39606

Notes: Variable compatibility results have been reported for this combination depending on the dopa depending on the dopamine hydrochloride formulation. Dopamine hydrochloride with citrate b

## About Merative

Merative provides data, analytics, and software for healthcare and government social services. With focused innovation and deep expertise, Merative works with providers, employers, health plans, governments, and life sciences companies to drive real progress. Merative helps clients orient information and insights around the people they serve to improve decision-making and performance.

Learn more at [www.merative.com](http://www.merative.com)

## Footnote

<sup>1</sup>About Our National Institute for Health and Care Excellence (NICE) Accreditation, <http://truvenhealth.com/products/micromedex/quick-reference/trusted-evidence/accreditation>

© Merative US L.P. 2024. All Rights Reserved.

Produced in the United States of America  
March 2024

Merative and the Merative logo are trademarks of Merative US L.P. Other product and service names might be trademarks of Merative or other companies.

The information contained in this publication is provided for informational purposes only. While efforts were made to verify the completeness and accuracy of the information contained in this publication, it is provided AS IS without warranty of any kind, express or implied. In addition, this information is based on Merative's product plans and strategy as of the date of this publication, which are subject to change by Merative without notice. Nothing contained in this publication is intended to, nor shall have the effect of, creating any warranties or representations from Merative, or stating or implying that any activities undertaken by you will result in any specific performance results. Merative products are warranted according to the terms and conditions of the agreements under which they are provided.

Product release dates, availability and/or capabilities referenced in this publication may change at any time at Merative's sole discretion, and are not intended to be a commitment to future product or feature availability in any way. Not all Merative products are available in all jurisdictions in which Merative operates.

MDX-6262232304 Rev 1.0

